MAIA
MAIA Biotechnology, Inc.
Biotechnology
Market Cap$50M
5Y Perf.-77.6%
Build Your Comparison
Side-by-side financial analysisMAIA
CYCN
IMVT
ACAD
Try popular comparisons:
Stock Comparison
MAIA vs CYCN vs IMVT vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
CYCN
Cyclerion Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-83.1%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.90B
5Y Perf.+716.0%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.61B
5Y Perf.+43.6%
MAIA vs CYCN vs IMVT vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  MAIA |  CYCN |  IMVT |  ACAD |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $50M | $14M | $6.90B | $3.61B |
| Revenue (TTM) | $0.00 | $2M | $0.00 | $1.10B |
| Net Income (TTM) | $-24M | $-5M | $-506M | $376M |
| Gross Margin | — | 100.0% | — | 91.5% |
| Operating Margin | — | -337.4% | — | 7.4% |
| Forward P/E | — | — | — | 54.2x |
| Total Debt | $0.00 | $0.00 | $72K | $52M |
| Cash & Equiv. | $8.66B | $3M | $902M | $178M |
MAIA vs CYCN vs IMVT vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MAIA
CYCN
IMVT
ACAD
| Stock | Jul 22 | Jun 26 | Return |
|---|---|---|---|
| MAIA Biotechnology,… (MAIA) | 100 | 22.4 | -77.6% |
| Cyclerion Therapeut… (CYCN) | 100 | 16.9 | -83.1% |
| Immunovant, Inc. (IMVT) | 100 | 816.0 | +716.0% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 143.6 | +43.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MAIA vs CYCN vs IMVT vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Immunovant, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ACAD emerged as the overall leader. Track its performance:
MAIA
MAIA Biotechnology, Inc.
The Specific-Use Pick
MAIA plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
CYCN
Cyclerion Therapeutics, Inc.
The Secondary Option
CYCN lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 237.9% 10Y total return vs ACAD's -44.6%
- Lower volatility, beta 1.66, Low D/E 0.0%, current ratio 9.09x
- +110.9% vs MAIA's -25.7%
Best for: long-term compounding and sleep-well-at-night
ACAD
ACADIA Pharmaceuticals Inc.
The Income Pick
ACAD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.10
- Rev growth 11.9%, EPS growth 68.4%, 3Y rev CAGR 27.5%
- Beta 1.10, current ratio 3.83x
- 11.9% revenue growth vs IMVT's -22.2%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ACAD | 11.9% revenue growth vs IMVT's -22.2% |
| Quality / Margins | ACAD | 34.3% margin vs CYCN's -264.7% |
| Stability / Safety | ACAD | Beta 1.10 vs MAIA's 1.84 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  IMVT | +110.9% vs MAIA's -25.7% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs IMVT's -62.2% |
MAIA vs CYCN vs IMVT vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
Segment breakdown not available.
FY 2018
MAIA vs CYCN vs IMVT vs ACAD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGCYCN
Who Leads Where
ACAD leads in 2 of 6 categories
IMVT leads 1 • MAIA leads 0 • CYCN leads 0 • 2 tied
Explore the data ↓CYCNCyclerion Therapeutic…
0leads
MAIAMAIA Biotechnology, I…
0leads
IMVTImmunovant, Inc.
1leads
ACADACADIA Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs IMVTvs MAIAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD and IMVT operate at a comparable scale, with $1.1B and $0 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to CYCN's -2.6%. On growth, ACAD holds the edge at +9.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  MAIAMAIA Biotechnolog… |  CYCNCyclerion Therape… | IMVTImmunovant, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $2M | $0 | $1.1B |
| EBITDAEarnings before interest/tax | -$16M | -$7M | -$532M | $96M |
| Net IncomeAfter-tax profit | -$24M | -$5M | -$506M | $376M |
| Free Cash FlowCash after capex | -$20M | -$4M | -$407M | $212M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% | — | +91.5% |
| Operating MarginEBIT ÷ Revenue | — | -3.4% | — | +7.4% |
| Net MarginNet income ÷ Revenue | — | -2.6% | — | +34.3% |
| FCF MarginFCF ÷ Revenue | — | -180.0% | — | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% | — | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.5% | -35.7% | -14.1% | -81.8% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — CYCN and IMVT and ACAD each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… | IMVTImmunovant, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Market CapShares × price | $50M | $14M | $6.9B | $3.6B |
| Enterprise ValueMkt cap + debt − cash | -$8.6B | $11M | $6.0B | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.86x | -2.98x | -12.14x | 9.21x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 54.20x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 25.09x |
| Price / SalesMarket cap ÷ Revenue | — | 6.79x | — | 3.37x |
| Price / BookPrice ÷ Book value/share | 17.57x | 1.15x | 7.19x | 2.94x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 34.34x |
Evenly matched — CYCN and IMVT and ACAD each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-68 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACAD's 0.04x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs CYCN's 1/9, reflecting solid financial health.
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… | IMVTImmunovant, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -4.0% | -62.1% | -68.2% | +35.6% |
| ROA (TTM)Return on assets | -1.0% | -55.1% | -62.2% | +26.2% |
| ROICReturn on invested capital | — | -65.1% | — | +10.0% |
| ROCEReturn on capital employed | -4.8% | -55.5% | -68.3% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 | 2 | 6 |
| Debt / EquityFinancial leverage | — | — | 0.00x | 0.04x |
| Net DebtTotal debt minus cash | -$8.7B | -$3M | -$902M | -$126M |
| Cash & Equiv.Liquid assets | $8.7B | $3M | $902M | $178M |
| Total DebtShort + long-term debt | $0 | $0 | $72,000 | $52M |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | — |
ACAD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $31,304 today (with dividends reinvested), compared to $379 for CYCN. Over the past 12 months, IMVT leads with a +110.9% total return vs MAIA's -25.7%. The 3-year compound annual growth rate (CAGR) favors IMVT at 15.7% vs MAIA's -19.3% — a key indicator of consistent wealth creation.
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… | IMVTImmunovant, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -18.8% | +142.5% | +29.8% | -19.3% |
| 1-Year ReturnPast 12 months | -25.7% | +4.8% | +110.9% | -3.0% |
| 3-Year ReturnCumulative with dividends | -47.4% | -25.3% | +55.0% | -14.3% |
| 5-Year ReturnCumulative with dividends | -70.9% | -96.2% | +213.0% | -22.6% |
| 10-Year ReturnCumulative with dividends | -70.9% | -98.7% | +237.9% | -44.6% |
| CAGR (3Y)Annualised 3-year return | -19.3% | -9.3% | +15.7% | -5.0% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMVT and ACAD each lead in 1 of 2 comparable metrics.
Risk & Volatility
ACAD is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than MAIA's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 92.7% from its 52-week high vs CYCN's 38.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… | IMVTImmunovant, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.84x | 1.12x | 1.66x | 1.10x |
| 52-Week HighHighest price in past year | $3.19 | $8.48 | $36.27 | $27.81 |
| 52-Week LowLowest price in past year | $0.87 | $1.03 | $14.32 | $19.69 |
| % of 52W HighCurrent price vs 52-week peak | +40.8% | +38.3% | +92.7% | +75.8% |
| RSI (14)Momentum oscillator 0–100 | 47.8 | 57.1 | 57.9 | 47.9 |
| Avg Volume (50D)Average daily shares traded | 771K | 232K | 1.9M | 1.4M |
Evenly matched — IMVT and ACAD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: IMVT as "Buy", ACAD as "Buy". Consensus price targets imply 64.9% upside for ACAD (target: $35) vs 29.9% for IMVT (target: $44).
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… | IMVTImmunovant, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $43.67 | $34.78 |
| # AnalystsCovering analysts | — | — | 23 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.9% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IMVT leads in 1 (Total Returns). 2 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 2 of 6 categories
Loading custom metrics...
MAIA vs CYCN vs IMVT vs ACAD: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is MAIA or CYCN or IMVT or ACAD a better buy right now?
For growth investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus 3. 7% for Cyclerion Therapeutics, Inc. (CYCN). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MAIA or CYCN or IMVT or ACAD?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +213. 0%, compared to -96. 2% for Cyclerion Therapeutics, Inc. (CYCN). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus CYCN's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MAIA or CYCN or IMVT or ACAD?
By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.
(ACAD) is the lower-risk stock at 1. 10β versus MAIA Biotechnology, Inc. 's 1. 84β — meaning MAIA is approximately 67% more volatile than ACAD relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MAIA or CYCN or IMVT or ACAD?
By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.
(ACAD) is pulling ahead at 11. 9% versus 3. 7% for Cyclerion Therapeutics, Inc. (CYCN). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -1. 5% for Immunovant, Inc.. Over a 3-year CAGR, CYCN leads at 91. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MAIA or CYCN or IMVT or ACAD?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -170. 1% for Cyclerion Therapeutics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -239. 8% for CYCN. At the gross margin level — before operating expenses — CYCN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is MAIA or CYCN or IMVT or ACAD more undervalued right now?
Analyst consensus price targets imply the most upside for ACAD: 64.
9% to $34. 78.
07Which pays a better dividend — MAIA or CYCN or IMVT or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is MAIA or CYCN or IMVT or ACAD better for a retirement portfolio?
For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). MAIA Biotechnology, Inc. (MAIA) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -44. 6%, MAIA: -70. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between MAIA and CYCN and IMVT and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MAIA is a small-cap quality compounder stock; CYCN is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.